Stockwinners Market Radar for June 29, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EDT Cathie Wood's ARK Investment bought 69K shares of Verve Therapeutics today

18:28 EDT Circor up 3% at $55.60 after entering merger deal with KKR

18:23 EDT Avita Medical submits PMA supplement to FDA for RECELL GO - AVITA Medical "announced its submission of a premarket approval, or PMA, supplement to the U.S. Food and Drug Administration for RECELL GO(TM). The supplement follows the original PMA of its RECELL Autologous Cell Harvesting Device and subsequent PMA supplements. With its innovative capabilities, RECELL GO revolutionizes the current, manually operated RECELL device by eliminating the need for manual management of skin samples. RECELL GO will utilize single-use processing cartridges integrated into a durable AC powered processing device. The automated workflow streamlines the critical steps of enzyme incubation, buffer rinse, mechanical disaggregation, and filtering, transforming the production process of Spray-On Skin(TM) Cells."

18:03 EDT Environmental Tectonics awarded $17.3M contract for sterilization equipment - Environmental Tectonics announced it has been awarded a $17.3M contract from a multi-national medical device manufacturer. The contract includes four, thirty pallet ethylene oxide sterilization chambers and four, thirty pallet vacuum aeration chambers. "This contract reflects ETC Sterilization Systems Group's dedication to innovation in our mechanical designs, control systems and software expertise to meet the challenging requirements of this market," states Eric Hunnicutt, ETC Director of EO Sterilizer Sales. ETC's Sterilization Systems Group offers Steam and Ethylene Oxide Sterilizer Systems, Vacuum Dryers, Software Systems, and project management services to the Medical Device, Pharmaceutical, Biotechnology, and Life Science industries. ETC's systems are specially designed to meet unique process systems challenges.

18:02 EDT Renalytix says FDA grants De Novo marketing authorization for KidneyIntelX.dkd - Renalytix announced that the U.S. Food and Drug Administration has granted De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. This affirms KidneyIntelX as a first-in-class, artificial intelligence enabled prognostic testing platform to guide care management for adults with type 2 diabetes and early-stage chronic kidney disease. Renalytix believes FDA authorization will lead to increasing test adoption, informing clinical guidelines, expanding insurance coverage, and pursuing additional international regulatory approvals. "Meeting the rigorous safety, clinical and analytical validation, and scientific data requirements of an FDA review, from Breakthrough Device designation to De Novo marketing authorization, is a landmark event for health care providers and patients with diabetic kidney disease," said James McCullough, CEO of Renalytix. "With this approval a new class, Prognostic Test for Assessment of Chronic Kidney Disease Progression, has been established by the FDA, providing a roadmap for future expansion of KidneyIntelX into new indications and products."

17:51 EDT Environmental Tectonics awarded 17.3M contract for sterilization equipment - Environmental Tectonics announced it has been awarded a $17.3M contract from a multi-national medical device manufacturer. The contract includes four, thirty pallet ethylene oxide sterilization chambers and four, thirty pallet vacuum aeration chambers. "This contract reflects ETC Sterilization Systems Group's dedication to innovation in our mechanical designs, control systems and software expertise to meet the challenging requirements of this market," states Eric Hunnicutt, ETC Director of EO Sterilizer Sales. ETC's Sterilization Systems Group offers Steam and Ethylene Oxide Sterilizer Systems, Vacuum Dryers, Software Systems, and project management services to the Medical Device, Pharmaceutical, Biotechnology, and Life Science industries. ETC's systems are specially designed to meet unique process systems challenges.

17:47 EDT Calithera: Special meeting for purpose of voting on dissolution cancelled - Calithera Bioscience announced that it was unable to achieve a quorum of stockholders at its special meeting of stockholders scheduled to be held on June 29 or the purpose of approving the Company's Plan of Complete Liquidation and Dissolution. In January 2023, the Company announced its intention to commence an orderly wind down of the Company's business and operations. After consulting with its proxy solicitation advisors, the Company concluded that further attempts to solicit proxies for the Special Meeting would in all likelihood not allow it to achieve a quorum, and as a result has cancelled.

17:41 EDT Manulife Financial takes minority stake in Parreira Almond, no terms - Manulife Investment Management has announced a minority partnership with Parreira Almond Holding Company, PAHC, a family-owned almond hulling, shelling, processing, and marketing company, on behalf of its clients. The minority investment will position PAHC and its wholly owned subsidiaries, RPAC and Parreira Almond Processing Company for future growth as well as continue to provide a consistent volume of high-quality California-grown and U.S.-grown almonds through both investments in the existing operations and from further acquisitions.

17:32 EDT First Hawaiian announces senior leadership transitions - First Hawaiian announced the upcoming retirements of three members of its senior leadership team: Vice Chairman and Chief Risk Officer, Ralph Mesick; Vice Chairman and Chief Lending Officer, Lance Mizumoto; and Executive Vice President & Chief Human Resources Officer, Iris Matsumoto. In anticipation of these retirements, First Hawaiian announced the promotions of the individuals that will succeed them. Lea Nakamura, Deputy Chief Risk Officer, will be appointed as Chief Risk Officer, and Darlene Blakeney, Executive Vice President and Division Manager for the Corporate Banking Division of First Hawaiian Bank and President of First Hawaiian Leasing, will be appointed as Chief Lending Officer, effective July 1, and October 1, respectively. Each will join the First Hawaiian Senior Management Committee upon her respective appointment. Additionally, Gina Anonuevo, Chief Compliance Officer of the Bank, will take over as Chief Human Resources Officer effective December 1. As Chief Human Resources Officer, Gina will continue to serve as a member of the First Hawaiian Senior Management Committee.

17:09 EDT Pinterest's former CFO Mongenfeld sells $1.6M in common stock - In a regulatory filing, Pinterest disclosed that its former CFO Todd Morgenfeld sold 60.7K shares of common stock in a total transaction size of $1.6M.

17:04 EDT AbbVie names Robert Michael president, COO - According to a regulatory filing, effective June 29, 2023, Robert A. Michael has been appointed President and Chief Operating Officer of AbbVie. Michael will continue to oversee AbbVie's global commercial and financial operations. He will also be responsible for operations, human resources, business development and corporate strategy.

17:02 EDT Donaldson acquires Univercells Technologies - Donaldson acquired Univercells Technologies, a global producer of biomanufacturing solutions for cell and gene therapy research, development and commercial manufacturing. Univercells Technologies' product offering includes the unique scale-X single-use structured fixed-bed bioreactor for the intensified production of viruses used in cell and gene therapy, viral vaccines and other therapeutics. In addition, the company's automated NevoLine Upstream platform incorporates industry-standard filtration to provide integrated up- and mid-stream processing capabilities in a single unit. Headquartered in Nivelles, Belgium, Univercells Technologies has over 100 employees globally. The Company generated approximately EUR10M of revenue in calendar 2022 and was acquired for cash consideration of EUR136M on a cash-free, debt-free basis and subject to closing adjustments. Univercells Technologies is being acquired from Gamma Biosciences and Univercells SA and will be a part of the Donaldson Life Sciences segment. Baker McKenzie acted as legal advisors to Donaldson.

17:01 EDT Root down 16% on announcement company has not received actionable proposal

16:56 EDT Adicet Bio director buys $1.83M in common stock - In a regulatory filing, Adicet Bio disclosed that its director Carl Gordon bought 875K shares of common stock on June 27th in a total transaction size of $1.83M.

16:47 EDT Oil-Dri Corporation of America to implement price increases on clay absorbents - Oil-Dri Corporation of America announced that it will implement price increases on its industrial and automotive clay absorbents, effective September 1. These price increases will range from 10% to 15%, depending on the product.

16:45 EDT UDR announces formation of $510M joint venture - UDR and GRESB 5 Star rated company for its sustainability leadership, announced that it has closed a $510M joint venture with LaSalle Investment Management. The Company and the Partner intend to grow the joint venture over time through the acquisition of high-quality, well-located communities with operational upside that can be recognized through the implementation of UDR's industry-leading operating platform. Under the terms of the agreement, UDR will: initially contribute four communities totaling 1,328 apartment homes into the joint venture; retain a 51%ownership in the communities included in the joint venture; and, receive approximately $250M in cash proceeds. The joint venture will initially have no debt. The value of the seed portfolio is based on a low-5% effective forward yield, and the Company expects the transaction to be accretive to FFOA and cash flow per share in the first year of the venture. The Company serves as the manager of the joint venture and will earn asset management, property management, financing, and construction management fees. For new acquisitions made through the venture, the Company will earn acquisition fees and the potential to earn a promoted return should certain return hurdles be achieved. "We are pleased to establish a new joint venture with such a high-quality partner," said Tom Toomey, UDR's Chairman and CEO. "The venture validates the success of UDR's operating platform, innovation, and unique value creation mechanisms, which have led to the highest controllable operating margin among our peer group and earnings per share growth that is consistently above the peer average. Additionally, the venture expands UDR's strategy of diversifying among capital sources that provide the Company the ability to execute accretive investment opportunities across economic and market cycles. We look forward to growing this venture with our Partner over time to the benefit of our stakeholders through increased operating scale, densification, and earnings accretion."

16:43 EDT UDR forms $510M joint venture with LaSalle Investment - UDR has closed a $510M joint venture with LaSalle Investment. The company and the partner intend to grow the joint venture over time through the acquisition of high-quality, well-located communities with operational upside that can be recognized through the implementation of UDR's operating platform. UDR will initially contribute four communities totaling 1,328 apartment homes into the joint venture; retain a 51% ownership in the communities included in the joint venture; and receive approximately $250M in cash proceeds. The joint venture will initially have no debt. The value of the seed portfolio is based on a low-5% effective forward yield, and the company expects the transaction to be accretive to FFOA and cash flow per share in the first year of the venture. The company serves as the manager of the joint venture and will earn asset management, property management, financing, and construction management fees. For new acquisitions made through the venture, the company will earn acquisition fees and the potential to earn a promoted return should certain return hurdles be achieved.

16:35 EDT Aurinia Pharmaceuticals trading resumes

16:32 EDT Endo launches first generic version of Merck's Noxafil in the U.S. - Endo International (ENDP) announced that its Par Sterile Products business has begun shipping posaconazole injection (18 mg/mL), the first generic version of Merck's (MRK) Noxafil in the U.S., following final approval from the U.S. FDA of its Abbreviated New Drug Application. According to IQVIA, Noxafil vial sales were approximately $25M for the 12 months ended May 31, 2023.

16:23 EDT Emerson Electric COO Flavin sells 48,718 common shares - In a regulatory filing, Emerson Electric COO Lisa Flavin disclosed the sale of 48,718 common shares of the company on June 27 at a price of $89.6547 per share.

16:19 EDT Babylon Holdings trading halted, news dissemination

16:17 EDT Absolute Software approves acquisition by Crosspoint Capital - Absolute Software announces that its Securityholders have approved the acquisition of all of the outstanding shares of the Company by 1414364 B.C. LTD., an affiliate of Crosspoint Capital Partners, L.P. by way of a statutory plan of arrangement at the special meeting of Securityholders held today.

16:16 EDT Nike reports Q4 Direct sales $5.5B, up 15% - Revenues for the NIKE Brand were $12.2 billion, up 5 percent on a reported basis and up 8 percent on a currency-neutral basis, with growth across all brands, channels and geographies. NIKE Direct revenues were $5.5 billion, up 15 percent compared to prior year and up 18 percent on a currency-neutral basis, led by NIKE-owned stores growth of 24 percent and NIKE Brand Digital growth of 14 percent. Revenues for Converse were $586 million, down 1 percent on a reported basis and up 1 percent on a currency-neutral basis, led by double-digit growth in Asia, offset by declines in Europe.

16:14 EDT Toll Brothers Chairman Yearley sells $3.9M in company shares - Chairman of Toll Brothers Douglas Yearly disclosed the sale of 50,000 shares of stock at $78.63 per share after exercise at $32.49 per share, on June 28, for a transaction amount of $3,931,450.

16:10 EDT Doma 1-for-25 reverse stock split to become effective June 29 - Doma Holdings announced that it had filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the previously announced 1-for-25 reverse stock split of the Company's common stock, par value $0.0001 per share and a corresponding reduction in authorized shares of capital stock of the Company. The Reverse Stock Split and corresponding capital stock adjustment will become effective at 11:59 p.m. Eastern Daylight Time on Thursday, June 29, 2023. The Common Stock will begin trading on a split-adjusted basis when the markets open on Friday, June 30, 2023, under the existing trading symbol "DOMA" and new CUSIP number: 25703A 203. As a result of the Reverse Stock Split, every 25 shares of the Company's issued and outstanding Common Stock will automatically be converted into one share of issued and outstanding Common Stock and the number of authorized shares will be adjusted on the same split adjusted basis. No fractional shares will be issued as a result of the Reverse Stock Split. Instead, stockholders who otherwise would be entitled to receive fractional shares of Common Stock will be entitled to receive cash. The Reverse Stock Split affects all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's outstanding Common Stock, except for adjustments that may result from the treatment of fractional shares. All outstanding options, warrants, restricted stock units, and similar securities entitling their holders to receive or purchase shares of Common Stock will be adjusted as a result of the Reverse Stock Split, as required by the terms of each security.

16:09 EDT Root has not received any actionable proposal that enhances value - Root, the parent company of Root Insurance Company, issued the following statement: "Root's Board of Directors has always considered and evaluated, and will continue to consider and evaluate, any bona fide proposal or opportunity to enhance shareholder value in accordance with its fiduciary duties. At this time Root is not in receipt of any proposal that is either actionable or in the best interests of Root's shareholders. Root does not undertake any responsibility to update this statement in the future."

16:07 EDT Accolade reports Q1 EPS (52c), consensus (62c) - Reports Q1 revenue $93.23M, consensus $90.3M. "Our consistently strong financial results reinforce our belief that an advocacy-led care delivery strategy is the key to transforming the U.S. healthcare system. We are seeing the proof points in our growing customer base and sales momentum, and also through our customers' outcomes, engagement and measurable ROI. We are especially excited by the growth we are witnessing in virtual primary care, which is the key to people living their healthiest lives. For too long, healthcare has been a series of siloed episodes. An advocacy-led care delivery strategy facilitates a coordinated patient journey and tighter collaboration across the healthcare ecosystem, while delivering better health outcomes and tremendous customer satisfaction," said Rajeev Singh, Accolade CEO.

16:06 EDT Aurinia Pharmaceuticals to explore strategic alternatives - Aurinia Pharmaceuticals "announced that its Board of Directors has initiated an exploration of strategic alternatives. As part of this process, the Board will consider a wide range of options for the company including, but not limited to, a potential sale, merger, or other strategic transaction. There can be no assurance that this process will result in the company pursuing a particular transaction or other strategic outcome. Aurinia has not set a timetable for completion of this process, and it does not intend to disclose further developments unless and until it determines that further disclosure is appropriate or necessary. To assist in the review process, Aurinia has retained JP Morgan as its financial advisor, Skadden, Arps, Slate, Meagher & Flom, LLP as its US legal counsel, and Borden Ladner Gervais LLP as its Canadian legal counsel."

16:00 EDT Aurinia Pharmaceuticals trading halted, news pending

14:36 EDT BioMarin says FDA approves gene therapy Roctavian - BioMarin Pharmaceutical announced that the United States Food and Drug Administration approved ROCTAVIAN gene therapy for the treatment of adults with severe hemophilia A without antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. The one-time, single-dose infusion is the first approved gene therapy for severe hemophilia A in the U.S. ROCTAVIAN was first approved by the European Medicines Agency in August 2022. "Adults with severe hemophilia A face a lifelong burden, with frequent infusions and a high risk of health complications, including uncontrolled bleeding and irreversible joint damage," said Dr. Steven Pipe, professor of pediatrics and pathology at the University of Michigan and an investigator in the Phase 3 study. "The approval of ROCTAVIAN, as the first gene therapy for severe hemophilia A, has the potential to transform the way we treat adults based on years of bleed control following a single, one-time infusion."

13:52 EDT VW's Electrify America to add Tesla's NACS connector by 2025 - Volkswagen's (VWAGY) Electrify America announced it will add Tesla's (TSLA) North American Charging Standard, or NACS, connector to Electrify America and Electrify Canada's fast charging networks as part of the company's commitment to broaden charging solutions for electric vehicle drivers today and in the future. Electrify America will continue to provide the Combined Charging System connector throughout its network as it transitions to also support automakers adding NACS charging ports. The company will work to offer a NACS connector option at existing and future charging stations by 2025 to make charging as convenient as possible for EV owners. "Since our founding, we have focused on building an inclusive and open hyper-fast charging network to facilitate the adoption of electric vehicles," said Robert Barrosa, president and CEO of Electrify America. "We look forward to continuing to support industry-wide standards that increase vehicle interoperability and streamline public charging."

13:50 EDT Donerail Group urges Stratasys board to terminate Desktop Metal deal - The Donerail Group, a large shareholder of Stratasys (SSYS), with a beneficial ownership interest of approximately 2.3% of the Company's outstanding shares, released a letter to Stratasys' Board of Directors, which read in part, "Most specifically, we have concerns regarding the Board's clear, unconscionable, and continued refusal to engage with bona fide suitors regarding a sale of the Company over the past two years. Such fiduciary negligence needs to be rectified immediately. As the Company disclosed in a June 20th regulatory filing, since January of 2021, Stratasys has been on the receiving end of at least 12 unsolicited acquisition proposals from at least 3 separate bona fide acquirers. We also believe that the Board would receive additional acquisition interest if it would indicate a willingness to seriously entertain it. Implied acquisition premiums of the disclosed 12 unsolicited acquisition proposals have been attractive, with one proposal exceeding over 60% from the trading price at the time of the offer. In 11 of those 12 unsolicited acquisition proposals, Stratasys rejected the unsolicited proposal without engagement. Such blind and inconceivable rejections have cost Stratasys shareholders dearly. In the one unsolicited acquisition offer that was made of which the Board did, in fact, engage upon - the March 2023 Desktop Metal Incorporated (DM) proposal - the premium offered was the lowest of all other unsolicited offers and subsequently ended not in a sale of SSYS, but rather, what has turned into a highly risky bet-the-company merger for Stratasys...Tuesday morning, we watched with great interest as two separate, attractive, unsolicited offers were presented to Stratasys shareholders - one of which objectively serves as a highly attractive alternative for SSYS shareholders to the Desktop Metal proposed transaction. In fact, we believed that the prior 3D Systems Corporation's (DDD) offer - and their likely ability to increase their bid - was sufficiently compelling to warrant engagement with them vis-a-vis the Desktop Metal proposed transaction's value offered and precisely the valuation work that we had endeavored to highlight to the Board in a meeting - a request that was, again, rejected. As it stands today, 3D Systems' revised, increased proposal offers SSYS shareholders a combination with a highly complementary strategic party in a cash and stock deal valuing Stratasys at an over 27% premium to Monday's closing trading price. We do not believe that the Board can reject the obvious any longer: a 3D Systems transaction is significantly more compelling than the current alternatives and warrants immediate engagement...In this instance, we encourage the Board to follow its commitment to "work for shareholders" and terminate the Desktop Metal deal in favor of a more attractive deal."

13:36 EDT Intuit working with OpenAI to accelerate GenAI-driven application development - Intuit announced that it is working with OpenAI to accelerate generative AI-driven application development on its proprietary Intuit generative AI operating system "in support of the company's mission to power prosperity around the world for more than 100M consumer and small business customers," the company said. "Intuit is creating breakthrough product experiences on Intuit GenOS and we are excited to be working with OpenAI using their industry-leading large language models to accelerate our innovation," said Marianna Tessel, Chief Technology Officer at Intuit. "We're harnessing the power of generative AI to power prosperity for more than 100 million customers around the world by transforming the way people manage their finances with full confidence."

13:30 EDT Accenture names Rajendra Prasad Chief Information and Asset Engineering Officer - Accenture announced that effective July 1, Rajendra Prasad will become Accenture's Chief Information and Asset Engineering Officer, a new role that oversees all internal technology development and support for Accenture systems and Accenture assets for clients. Prett succeeds Gloria Samuels in the role of global lead for Accenture's Workday Business Group.

13:05 EDT Qurate's QVC, HSN launch livestream video shopping experience on Amazon Freevee - Qurate Retail Group (QRTEA) announced the launch of QVC and HSN linear channels on Amazon Freevee (AMZN). QVC and HSN are the first and only livestream shopping channels on the service, the company said in a statement. In addition to QVC and HSN, Qurate Retail Group will be launching The Big Dish, its first FAST Channel. QVC and HSN will offer Freevee customers approximately 40 hours a day of live vCommerce programming across both channels, featuring "premier brands and fresh new products presented by celebrities, influencers and other interesting personalities."

12:32 EDT Addentax Group announces 1-for-10 reverse share split - Addentax Group announced that the Company's board of directors exercised its discretion to effect a 1-for-10 reverse split of its common stock shares on June 8, 2023 and is expected to become effective on June 30, 2023. Upon the effectiveness of the reverse share split, Addentax shareholders will receive one new common stock share of Addentax for every ten shares they hold. Addentax's common stock shares are expected to begin trading on a split-adjusted basis when the market opens on June 30, 2023. The reverse share split is expected to lead Addentax's common stock shares to trade at approximately ten times the price per share at which it trades prior to the effectiveness of the reverse share split. Addentax, however, cannot assure that the price of its common stock shares after the reverse split will reflect the 1-for-10 reverse split ratio, that the price per share following the effective time of the reverse split will be maintained for any period of time, or that the price will remain above the pre-split trading price. As of June 29, 2023, there were 37,395,420 of Addentax's common stock outstanding. Effecting the Reverse Stock Split will reduce that amount to 3,739,542.

12:00 EDT Virgin Galactic falls -7.2% - Virgin Galactic is down -7.2%, or -34c to $4.40.

12:00 EDT ATI Physical Therapy falls -11.2% - ATI Physical Therapy is down -11.2%, or -$1.16 to $9.20.

12:00 EDT Greenbrier rises 26.0% - Greenbrier is up 26.0%, or $8.43 to $40.91.

11:51 EDT Virgin Galactic says Galactic01 spaceship has 'landed smoothly' - Virgin Galactic tweeted: "Welcome back to Earth, #Galactic01! Our pilots, crew and spaceship have landed smoothly at @Spaceport_NM." Reference Link

11:27 EDT SEC charges former DWAC Board Member, others for insider trading - The Securities and Exchange Commission has filed insider trading charges against Bruce Garelick, a former board member of Digital World Acquisition Corporation, a special purpose acquisition company; Michael Shvartsman and his firm Rocket One Capital; and Gerald Shvartsman for trading in advance of DWAC's October 2021 announcement that it had reached an agreement to acquire Trump Media & Technology Group Corp. The SEC's complaint alleges that, after DWAC appointed Garelick as a member of its board of directors in September 2021, Garelick learned about, and voted on, material nonpublic actions and updates regarding the negotiations between DWAC and its merger target, TMTG. Garelick, who was separately employed as the chief strategy officer at Rocket One Capital, then allegedly shared those updates with his boss, Michael Shvartsman, who in turn shared them with his brother, Gerald Shvartsman. Each then allegedly purchased DWAC securities on the open market based on the material nonpublic information they learned about DWAC. Michael Shvartsman placed his trades through an account in the name of Rocket One Capital. The defendants then sold their positions shortly after DWAC announced it had signed a merger agreement with TMTG and collectively realized illicit profits of more than $22.9M from those trades. The complaint further alleges that, despite being a DWAC director and thus having certain reporting obligations, Garelick failed to file SEC Forms 4 and 5 related to his transactions in DWAC securities. The SEC's complaint, filed in the United States District Court for the Southern District of New York, charges the defendants with violating the antifraud provisions of the federal securities laws and also charges Garelick with violating the reporting obligations of Section 16 of the Exchange Act. The complaint seeks permanent injunctive relief, disgorgement of ill-gotten gains, prejudgment interest, and civil penalties against all defendants, as well as officer and director bars against Garelick and Michael Shvartsman. In a parallel action, the U.S. Attorney's Office for the Southern District of New York announced criminal charges against Garelick and the Shvartsmans.Reference Link

11:24 EDT Former Pfizer statistician charged by SEC with insider trading - The SEC announced insider trading charges against Amit Dagar, a former Pfizer Inc. employee, and his close friend and business partner, Atul Bhiwapurkar, for trading in advance of the company's November 5, 2021, announcement that a randomized, double-blind study of its COVID-19 antiviral treatment, Paxlovid, was successful. Following that announcement in which Pfizer's CEO referred to the news as a "game-changer" in the global efforts to "halt the devastation" of the pandemic, the company's stock price increased by nearly 11%, the largest single-day price move in the stock since 2009. According to the SEC's complaint, Dagar was a senior statistical program lead for the Paxlovid drug trial, which began in July 2021 as part of the company's efforts to address the global health pandemic. On the day before the Paxlovid announcement, the complaint alleges, Dagar learned material, nonpublic information about the success of the trial. The complaint alleges that Dagar's and Bhiwapurkar's trading generated approximately $214,395 and $60,300 respectively in illicit profits, which amounted to one-day investment returns of 2,458 percent and 791%. The SEC's complaint was filed in U.S. District Court for the Southern District of New York. Reference Link

11:14 EDT Southwest extends flight schedule through March 6, 2024, adds seasonal service - Southwest Airlines extended its flight schedule through March 6, 2024, enabling Customers to book their early 2024 getaways. Southwest also announced it is adding new seasonal nonstop service. Beginning Jan. 13, 2024, Southwest will offer service on Saturdays between Omaha, Neb., and Fort Lauderdale/Hollywood, Fla. Southwest will also resume several seasonal routes beginning as early as Jan. 8, 2024, bringing convenient flights for Customers to take a break from winter weather. Southwest will resume daily service beginning Jan. 8, 2024, between Dallas and Fort Myers, Fla. and between Dallas and Palm Springs, Calif. A few days later, on Jan. 14, 2024, Southwest will resume flights on Sundays between Dallas and Louisville, Ky.

11:12 EDT Billtrust appoints Philip Ragona as CLO, Esther Pomeleo-Fowler as CCO - Billtrust announced four new executive appointments. Joining Billtrust are Philip Ragona, Chief Legal Officer, Nick Izquierdo, Executive Vice President, Payments and Esther Pomeleo-Fowler, Executive Vice President/Chief Customer Officer. In addition, Christy Green has been promoted to Executive Vice President, Professional Services. Prior to joining Billtrust, Phil served as Senior Vice President and Deputy General Counsel for the Americas at Paysafe. Nick spent 13 years at FLEETCOR, most recently as President, Global Strategy, driving strategic imperatives and midterm growth. Prior to Billtrust, Esther spent 14 years with Blackbaud, most recently as Head of Customer Experience where she led all aspects of its global enterprise customer success organization.

10:53 EDT Alkermes shareholders re-elect all seven company director nominees - Alkermes announced that, at the company's 2023 annual general meeting, shareholders voted to re-elect all seven of Alkermes' director nominees - Emily Peterson Alva, Shane M. Cooke, Richard B. Gaynor, M.D., Cato T. Laurencin, M.D., Ph.D., Brian P. McKeon, Richard F. Pops and Christopher I. Wright, M.D., Ph.D. Sarissa Capital Management LP nominees Alexander Denner, Ph.D., Patrice Bonfiglio and Sarah Schlesinger, M.D. failed to achieve the necessary votes for election. Additionally, all other company proposals were approved by shareholders. Nancy Wysenski, Lead Independent Director of Alkermes' Board of Directors, said, "We are pleased that all seven company nominees were re-elected to the board and appreciate the active engagement with our shareholders as well as their feedback and support. We believe this outcome is a reflection of our strong performance and robust corporate governance practices. Looking ahead, we remain focused on executing on our strategic priorities for the benefit of all shareholders, including our commitment to operational efficiency, disciplined capital allocation and profitability. We recognize that our work is far from done and look forward to continuing our active engagement with shareholders as we seek to drive significant value creation."

10:32 EDT SiriusPoint appoints Linda Lin as Chief Legal Officer - SiriusPoint has appointed Linda Lin as Chief Legal Officer, effective July 24. Lin will join SiriusPoint's Executive Leadership Team, reporting to CEO Scott Egan. Lin joins SiriusPoint from Coaction Global, formerly Prosight, where she led the legal, regulatory, compliance, product development and internal audit functions as General Counsel and Corporate Secretary. "Jimmy Yang, who stepped into the role of Interim General Counsel in February 2023, will work closely with Ms Lin to ensure a seamless handover and transition," the company stated.

10:02 EDT Mercury Systems appoints David Farnsworth as CFO - Mercury Systems announced the continuation of its previously announced Board of Directors and leadership refreshment process, with the appointments of: David Farnsworth as CFO, effective July 17, 2023. He was previously the CFO of HawkEye 360. Roger Krone, former Chairman and CEO of Leidos, as an independent director, effective June 28, 2023. He will also serve as a member of the Board's Nominating and Governance Committee. As previously announced, Michelle McCarthy, who has served as Interim CFO since January 2023, will remain in her role as Senior Vice President and Chief Accounting Officer.

10:00 EDT GoGreen Investments falls -5.3% - GoGreen Investments is down -5.3%, or -61c to $10.89.

10:00 EDT Freyr Battery rises 22.4% - Freyr Battery is up 22.4%, or $1.69 to $9.24.

10:00 EDT Carriage Services rises 25.0% - Carriage Services is up 25.0%, or $7.02 to $35.06.

09:47 EDT GoGreen Investments falls -5.6% - GoGreen Investments is down -5.6%, or -64c to $10.86.

09:47 EDT Carriage Services rises 18.6% - Carriage Services is up 18.6%, or $5.21 to $33.25.

09:47 EDT Greenbrier rises 20.8% - Greenbrier is up 20.8%, or $6.76 to $39.24.

09:40 EDT CMA application refused by Tribunal in Activision-Microsoft fight - In a ruling posted by the U.K. Competition Appeal Tribunal, the tribunal stated: "Without prior warning, on 28 June 2023, the CMA applied to adjourn the substantive hearing date of 28 July to 4 August 2023... The Tribunal has carefully considered the CMA's application. It has done so overnight, conscious that given the imminence of the substantive hearing, the parties need to know where they stand right away... The CMA's application is refused... We consider that the CMA has not paid sufficient heed to the true public interest in this case - which is the swift resolution of Microsoft's Notice. The CMA has chosen to re-visit a matter already decided (namely, an end July/early August hearing and not an October hearing) when there has been no material change of circumstance. Furthermore, the CMA has made this application indefensibly late, with no explanation. Finally, there has been no attempt by the CMA to explore - either with Microsoft or with the Tribunal - ways in which the burden might be eased." Reference Link

09:30 EDT Diana Shipping signs $100M term loan facility - Diana Shipping announced that on June 26, 2023, it signed a term loan facility with DNB Bank ASA for up to $100 million with maturity date up to December 2029, subject to mutually agreed margin reset at the end of the fourth year. Yesterday, it concluded the drawdown of $100 million, secured by ten vessels. The proceeds from the loan facility refinanced other loan facilities with an aggregate outstanding amount of approximately $68.7 million, namely two existing loan facilities with ABN AMRO Bank N.V. of approximately $31.4 million and of approximately $37.3 million related to the same ten vessels. The remaining proceeds may be used to pay transaction costs and expenses incurred in connection with the loan agreement and/or general corporate purposes. On June 20, 2023, The Company also signed a term loan facility with Nordea Bank Abp, filial i Norge for up to $22.5 million with maturity date in June 2028. On June 27, 2023, it concluded the drawdown of $22.5 million, secured by four vessels. The proceeds from the loan facility refinanced the existing loan facility with an outstanding amount of approximately US$20.9 million, with Nordea Bank Abp, filial i Norge related to the same four vessels. The remaining proceeds may be used to pay transaction costs and expenses incurred in connection with the loan agreement and/or general corporate purposes.

09:23 EDT AstraZeneca: Imfinzi + Imjudo demonstrate meaningful OS benefit for HCC patients - Updated results from the HIMALAYA Phase III trial showed AstraZeneca's IMFINZI or durvalumab plus IMJUDO demonstrated a sustained, clinically meaningful overall surviva OS benefit at four years for patients with unresectable hepatocellular carcinoma, HCC, who had not received prior systemic therapy and were not eligible for localized treatment. These results from HIMALAYA will be presented today at the 2023 European Society for Medical Oncology World Congress on Gastrointestinal Cancer in Barcelona, Spain. Bruno Sangro, MD Director of the Liver Unit and Professor of Internal Medicine at Clinica Universidad de Navarra, Pamplona, Spain and a lead investigator in the trial, said: "Historically, only seven percent of patients with advanced liver cancer have survived five years, making the HIMALAYA long-term survival data especially meaningful. One in four patients treated with the STRIDE regimen were still alive at four years, reinforcing this novel regimen as a standard of care in this setting."

09:14 EDT Polestar Automotive in pact with Tesla on new North American Charging Standard - Polestar (PSNY) has signed an agreement with Tesla (TSLA) to adopt the new North American Charging Standard, NACS, which will enable access to Tesla's expansive Supercharger network for all Polestar drivers in the United States and Canada..."This is a great win for our North American customers! We salute the pioneering work Tesla has done to speed up the adoption and increase the popularity of electric vehicles, and it's great to see the Supercharger network being made available in this way. With 12,000 charging points today, a number that will only keep growing, this move will greatly increase the rate of EV adoption in a key automotive region," says Thomas Ingenlath, CEO. The agreement applies to current and future Polestar models. To maintain compatibility with existing CCS public fast charging infrastructure in North America, future NACS-equipped Polestar vehicles will come with a CCS adapter.

09:09 EDT eXp Realty launches Boost program - eXp Realty announced the launch of its Boost program, designed to financially incentivize qualifying independent teams and brokerages to join eXp Realty. As part of this program, eXp Realty will provide financial incentives to independent teams and brokerages that are culturally aligned, have more than 50 agents and a minimum of $100M in sales volume in the originating country over the previous 12-month fiscal period. International qualifications to be released. Additional qualifications apply. Cannot be affiliated with any non-independent franchise.

09:08 EDT Capital Power executes contracts for solar, natural gas, batteries - Capital Power Corporation announced Execution of three long-term contracts in North Carolina and Ontario, totalling 287 megawatts of additional generation and energy storage capacity, Execution of a contract in the Ontario Independent Electric System Operator's Same Technology Upgrade Solicitation, Successful bid in the Ontario IESO's Expedited Long-Term RFP, and Updates on timing and costs of the Genesee Repowering Project in Alberta. The Company executed a 25-year, fixed price renewable power purchase agreement for 100% of the output from its Maple Leaf Solar project with Duke Energy Progress as part of the 2022 Duke Energy Solar Procurement Program. Maple Leaf is a 73 MWac solar development project in Selma, North Carolina. The construction of the Project is planned to begin in 2025 at a total cost of approximately US$165 million with an expected commercial operations date in the fourth quarter of 2026, pending completion of the Duke interconnection upgrades. Local zoning approvals were obtained in May 2023 and detailed design and permitting are underway. Capital Power has been an active participant in the Ontario IESO's expedited call for new power generation and capacity in high priority areas to help address the IESO's forecasted shortfall, which has resulted in five successful bids. Capital Power has: Executed two long-term contracts for the East Windsor Expansion with a term to 2040 and the York BESS project which is contracted until 2047 as part of the IESO's Expedited Long-Term RFP process. Both projects are expected to begin commercial operations in 2025. Executed a 3-year contract extension for the York Energy Centre associated with its successful bid in the Same Technology Upgrade Solicitation for approximately 38 MW. The upgrade will increase York's contracted capacity from 394 MW to 431 MW. The contract extension applies to the new contracted capacity of 431 MW and extends the current contract from 2032 to 2035. Previously been awarded a 6-year contract extension through the Same Technology Upgrade Solicitation for the Goreway Power Station. Been selected as a successful proponent for an approximately 22-year contract to 2047 for the Goreway BESS project as part of Category 2 of the IESO's Expedited Long-Term RFP. Capital Power expects to execute this contract by July 25, 2023. The project is expected to enter service in 2025. With the addition of these contracts, the Company will have more than 1,500 MW of contracted capacity in Ontario that support this key market's critical power needs and significantly increase Capital Power's contracted cash flow profile. As a result of construction delays on the Repowering Project, the Company is modifying the commissioning timelines for the repowered units. Simple cycle commissioning of Unit 1 is expected to commence in December 2023, approximately 60 days later than initially anticipated. Simple cycle commissioning for Unit 2 is expected to be further delayed and will begin in March 2024. Combined cycle commissioning is expected to begin in April 2024 and June 2024. The total capital costs for the Repowering Project have increased to $1.35 billion as a result of cost escalations and increased labour costs. The delay in commissioning is expected to have a modest impact on the full year 2023 AFFO and adjusted EBITDA guidance as the unfavourable impact will be offset across the portfolio. The Company expects to be above the midpoint of the guidance range despite an unforced outage at Genesee during periods of high pricing in June that dampened a strong start to the second quarter relative to the guidance provided in the Company's first quarter 2023 report. Management is currently evaluating the impact of commissioning delays on the Company's target of being off coal in 2023 and expects to provide additional information on the 2023 outlook and our off-coal target with the second quarter 2023 earnings release.

09:05 EDT Evelo Biosciences announces 1-for-20 reverse stock split - Evelo Biosciences announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time today, June 29, 2023, after close of trading on The Nasdaq Global Select Market. The Company's common stock is expected to commence trading on a split-adjusted basis when the markets open on June 30, 2023 under the existing trading symbol "EVLO." The new CUSIP number for the Company's common stock following the reverse stock split will be 299734 202. The primary goal of the reverse stock split is to increase the per share market price of the Company's common stock to meet the minimum per share bid price requirement for continued listing on The Nasdaq Global Select Market. As a result of the reverse stock split, every 20 shares of the Company's common stock issued and outstanding will be automatically reclassified into one new share of the Company's common stock.

09:04 EDT United Maritime sells remaining tanker. acquisition of Panamax Vessel - United Maritime announced that it has entered into an agreement with an unaffiliated third party for the sale of its remaining LR2 tanker vessel, the 2008-built M/T Epanastasea. The vessel is scheduled to be delivered to its new owner by mid-August 2023. The vessel's gross sale price is $37.5 million, and the transaction is subject to customary closing procedures. In addition, the Company has entered into an agreement to acquire a Panamax dry bulk vessel built in 2011 in Japan, with a cargo carrying capacity of 76,361 dwt and will be renamed M/V Exelixsea. The aggregate purchase price is $17.8 million and is expected to be funded with cash on hand, including the proceeds from the sale of the M/T Epanastasea. The Company is in advanced discussions with the lender of the M/T Epanastasea to roll over the $15.0 million loan secured by the M/T Epanastasea to the M/V Exelixsea under substantially the same terms. The vessel is expected to be delivered to the Company between August and October 2023. Stamatis Tsantanis, the Company's Chairman & Chief Executive Officer, stated: "The announced sale and acquisition transactions are a testament of our ability to generate significant profits for our shareholders. Since our initial public offering approximately one year ago, we have managed to execute a series of profitable transactions, reaching almost one million DWT, without diluting our shareholders. In addition, we have distributed $1.15 per share in cash dividends, which represents approximately 45% cash yield on our recent share price."

09:02 EDT BranchOut Food announces primary emphasis on the private label channel - BranchOut Food announces its primary emphasis on the private label channel as a key business strategy. While the company will continue to support and grow its robust brand portfolio, it believes that private label offers the most advantageous path for growth and profitability. With rising grocery prices, the demand for affordable alternatives has driven the popularity of private label products. BranchOut Food Inc. strategically aligns itself with the private label market to capitalize on this trend. Having already secured significant private label business from major retailers, the company aims to meet the growing consumer demand for high-quality, affordable options. The private label industry is valued at over $200B, with an annual growth rate exceeding 11%. BranchOut Food is well-positioned to supply this thriving market, leveraging its unique technology platform and strategic South American supply chain.

08:55 EDT BASF, Yara to evaluate low-carbon blue ammonia project at Gulf Coast - BASF and Yara Clean Ammonia are collaborating on a joint study to develop and construct a world-scale low-carbon blue ammonia production facility with carbon capture in the U.S. Gulf Coast region. The companies are looking into the feasibility of a plant with a total capacity of 1.2 to 1.4 million tons p.a. to serve the growing global demand for low-carbon ammonia. The companies plan to complete the feasibility study on the low-carbon blue ammonia production facility by end of 2023.

08:44 EDT Aquestive Therapeutics submits NDA filing for libervant - Aquestive submitted a New Drug Application to the U.S. Food and Drug Administration for approval of Libervant Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity in patients between two and five years of age. The Company received tentative approval for Libervant for the treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 12 years of age and older in August 2022, but is currently under an orphan drug block to market access until January 2027. Diastat Rectal Gel is the only treatment currently available to this patient population for this indication. The Company expects to hear from the FDA on the acceptance of, and issuance of a target action date on, this pediatric NDA within approximately two months.

08:42 EDT Cryoport selected by IVFAustralia as supply chain solutions provider - Cryoport has been selected by IVFAustralia, an Australian-based provider of full-service fertility care, IVF and related services as part of the Virtus Health network, as its exclusive supply chain solutions partner for its global reproductive material shipments. The multi-year agreement provides IVFAustralia and its fertility patients with the most advanced cryogenic shipping service in the world.

08:40 EDT Bridgeline Digital's HawkSearch selected by Valken Sports - Bridgeline Digital announced that Valken Sports has selected HawkSearch, Bridgeline's advanced AI powered search solution, to drive online business over its five ecommerce sites. The global distributor has committed to a 36-month agreement and chose HawkSearch to reinforce its digital presence after recently seeing the powerful features and search results demonstrated in HawkSearch's Multi-Store- Front Webinar webinar with BigCommerce and Obundle. Valken will leverage HawkSearch's Rapid UI framework to implement the solution with a tight turnaround deadline, and advanced functionality such as Recommendations and Smart Search to power revenue through more efficient online sales and an enhanced customer experience.

08:39 EDT Navitas Semiconductor, Plexim announce partnership to release PLECS models - Navitas Semiconductor and Plexim GmbH announce a partnership to release GeneSiC G3 SiC MOSFET and Gen 5 MPS diode PLECS thermal loss models for highly-accurate simulations of complete power electronics systems. "Accurate, empirically-based simulation models maximize the chance of first-time-accurate designs, accelerating time-to-market and time-to-revenue," noted Dr. Ranbir Singh, Navitas EVP for the GeneSiC business line. "For the power designer, understanding the leading-edge performance of GeneSiC MOSFETs and MPS diodes with detailed device characteristics, plus power, efficiency and thermal analysis is a critical competitive advantage."

08:38 EDT BioSig Technologies joins Webull Corporate Connect - BioSig Technologies is now actively participating on the Webull Corporate Connect platform, a specialized channel for direct investor communication and audience engagement, including Q&A.

08:37 EDT Ispire sees Q4 cannabis vaping product revenue at upper end of $12M-$15M - Ispire Technology announced that its fourth quarter 2023 revenue outlook for its cannabis vaping hardware would be on the upper end of the previously projected range of $12 million to $15 million. The Company's fiscal fourth quarter and full year 2023 ends on June 30, 2023. Ispire commenced marketing cannabis vaping hardware in mid-2020. The updated revenue projection from cannabis vaping hardware for the fourth quarter of 2023 is at $14 million to $15 million, on the upper end of the previous projection of $12 million to $15 million. The updated range represents year-over-year growth of 247% to 271% from the fourth quarter 2022, and represents sequential growth of 84% to 98%.Additionally, Ispire is projecting a fourth quarter total revenue at $29 million to $31 million, representing growth of 33% to 42% from the fourth quarter of 2022.

08:35 EDT NeuBase Therapeutics presents NHP repeat dosing data for Stealth Editors - NeuBase Therapeutics, announced a broad set of preclinical data, including non-human primate, NHP, repeat dosing data, for its Stealth Editors development program that demonstrate the ability to achieve gene editing with a non-immunogenic system. These preclinical data were featured in a poster presentation by Dr. Dani Stoltzfus, Vice President of Research at NeuBase, titled, "Stealth Editing With Peptide Nucleic Acids: A New Class of In Vivo Gene Editors," at the 28th American Peptide Symposium, which is being held in Scottsdale, AZ, from June 24-29, 2023. Overview of Preclinical Studies and Results Presented at APS 2023: Stealth Editors are Non-Immunogenic in Non-Human Primates - The Company demonstrated that Stealth Editors do not elicit an innate nor acquired immune response in NHPs as measured by a cytokine panel: Cynomolgus NHPs were given two doses of an intravenous administration, on days 1 and 29: vehicle control; MC3 lipid nanoparticle control; 0.10 mg/kg Stealth Editor encapsulated in an LNP; and 0.16 mg/kg Stealth Editor co-encapsulated with a single-stranded oligonucleotide donor in an LNP; On days 0, 1 and 29, blood was drawn and serum was assessed for IFN-gamma, IL-2, IL-6, IL-8, IL10 and IL-1beta cytokine induction using a Meso Scale Discovery multi-spot assay; Normal cytokine ranges were identified in healthy untreated cynomolgus monkeys by MSD; and All absolute values of cytokines were within the historical control ranges. The conclusion from these data is that Stealth Editors do not elicit innate nor acquired immune responses in the encapsulated format in which they would be administered systemically. The Company believes this is likely to be an important differentiator of its technology when transitioned to in vivo gene editing.

08:35 EDT Semper Paratus Acquisition Corp trading resumes

08:33 EDT ReShape Lifesciences signs preferred partner agreement with Hive Medical - ReShape Lifesciences announced the signing of a preferred partner agreement with Hive Medical. Hive's software suite leverages AI, machine-learning, SMS, and patient self-service technology to increase patient volume.

08:31 EDT GM Defense incorporates GM Defense Canada - GM Defense announced that it incorporated GM Defense Canada, in alignment with GM Defense International, which was established in 2022. As GM Defense expands and pursues additional international programs, the formation of GM Defense Canada will strengthen the business' ability to support efforts to modernize the Canadian Armed Forces.

08:26 EDT MEI Pharma: Letter to holders highlights value of Infinity Pharma transaction - MEI Pharma (MEIP) issued the following letter to shareholders reiterating the Board of Directors recommendation to vote FOR the pending transaction with Infinity Pharmaceuticals (INFI) in connection with the Company's special meeting on July 14..."The special meeting of shareholders at which you will have the opportunity to vote FOR our pending transaction with Infinity Pharmaceuticals, Inc. is fast approaching. Our transaction with Infinity provides our shareholders the opportunity to benefit from the upside potential of a combined company that is well capitalized and positioned to advance a diversified pipeline. To capture that opportunity, we encourage you to vote FOR the proposals related to the transaction in connection with the special meeting of shareholders on July 14"

08:20 EDT Xortx Therapeutics appoints James Fairbairn as interim CFO - The Company announces the appointment of James Fairbairn as Interim CFO. James Fairbairn was the Company's CFO from November 2018 through July 2021.

08:19 EDT A2Z Smart Technologies announces grant of equity incentive to officers - A2Z Smart Technologies announces the grant of incentive stock options to acquire a total of 245,000 common shares of the Company at an exercise price of C$2.48 per share, with such Options to vest over three years. The options expire five years from the date of grant. Additionally, the Company granted 165,000 Restricted Share Units which vest immediately. The Options and RSUs were granted to officers of the Company.

08:14 EDT PolyPid announces publication on potent antibacterial activity of D-PLEX100 - PolyPid announced a new publication highlighting the potent antibacterial activity of D-PLEX100 and its potential as an effective prophylactic drug against the most prevalent bacteria causing surgical site infections, including resistant strains. "This publication highlights the tremendous potential of D-PLEX100 in addressing the persistent challenge of surgical site infections, especially in an era of increased multidrug-resistant bacteria" stated Dikla Czaczkes Akselbrad, PolyPid's Chief Executive Officer. "The data showed the significant antibacterial activity of D-PLEX100 in pre-clinical and phase 2 clinical studies against a wide range of bacteria tested, including resistant ones. D-PLEX100's high anti-bacterial efficacy is attributed to its ability to support high local doxycycline concentration over a prolonged period in the surgical site and confirm its prophylactic potential against a wide range of antibiotic resistant bacteria, addressing a critical need in hospital care." The efficacy and safety of D-PLEX100 for the prevention of abdominal colorectal SSIs are currently being further evaluated in the SHIELD II Phase 3 clinical trial. Top-line results are expected in mid-2024.

08:14 EDT Jin Medical announces joint venture with Shanghai Sdoma Smart Technology - Jin Medical announced that the Company's variable interest entity, Changzhou Zhongjin Medical Equipment has entered into an investment agreement with Shanghai Sdoma Smart Technology to form a joint venture dedicated to the production and sales of a range of high-quality electric wheelchair and mobility scooter products. Pursuant to the Agreement, the JV will be established in Shanghai, with an estimated investment amount of up to RMB50 million in the next three years, 60% of which shall be contributed by JinMed and the remaining 40% shall be contributed by Sdoma. Erqi Wang, Chairman and CEO of the Company commented: "The formation of the JV is a significant milestone for both JinMed and Sdoma. As a mobility scooter product company with internet business attributes, Sdoma has developed mature internet marketing system, high marketing efficiency, and has quickly grown its market share and brand awareness in recent years, leading strong sales in Chinese market. JinMed has been committed to innovation and R&D in the field of assistive mobility scooter products for decades, and has achieved remarkable results in the upgrade of product quality and brand awareness in the industry over the years. The JV will further integrate JinMed's advantages in electric mobility products and Sdoma's strengths in online and offline channels and marketing, so that to enhance the market penetration of our electric mobility scooter products, and bring stable growth to our business of daily living aids products."

08:13 EDT Wearable Devices completes development of bidirectional plugin for Unity - Wearable Devices announced the completion of the development of its new bidirectional plugin for Unity, a game engine supporting desktop, mobile, console, virtual reality and augmented reality platforms, establishing a live communication channel between the Unity game engine and the Mudra Inspire neural input wristband. The innovative plugin integrates touchless interaction and control into Unity supported platforms, expanding software development opportunities and enabling commercial companies and enterprises to create increasingly customized experiences for their users.

08:11 EDT RenovoRx: RenovoGem delays cancer progression in LAPC - RenovoRx presented new positive data on progression-free survival, PFS, from the pivotal Phase III open label TIGeR-PaC study of RenovoGem in locally advanced pancreatic cancer LAPC .The interim data was featured as a late-breaking oral presentation at the 2023 ESMO World Congress on Gastrointestinal Cancer, and presented by Michael J. Pishvaian, M.D, Johns Hopkins Medicine and Principal Investigator of the TIGeR-PaC study. The interim analysis demonstrated an eight-month median PFS benefit, 15 versus 7 months, in delaying the progression of cancer for patients receiving treatment with RenovoGem versus standard-of-care. PFS is the measure of the length of time from study randomization to either death or progression of disease. "Clinical practice has been waiting decades for a meaningful advancement in the standard of care for pancreatic cancer treatment, with less toxicity and better outcomes. The new data from the TIGeR-PaC interim results support that RenovoGem has the potential to more than double progression-free survival compared to systemic chemotherapy alone in this difficult-to-treat cancer, which demonstrates support for a new treatment standard," said Michael J. Pishvaian, M.D of the TIGeR-PaC study. "This data has the potential to be a paradigm-shifting treatment for patients at risk of cancer progression, including those who have limited well-tolerated options."

08:11 EDT Sangamo, Voyager Therapeutics enter license agreement - Sangamo (SGMO) and Voyager Therapeutics (VYGR) announced the parties have entered into a definitive license agreement for a potential treatment of prion disease. Using its proprietary epigenetic regulation platform, Sangamo has developed zinc finger transcriptional regulators which it believes can specifically and potently block expression of the prion protein, the pathogenic driver of prion disease. Sangamo's ZF-TRs have been shown in animal models to significantly reduce expression of the prion protein in the brain, extend life span and limit formation of toxic prion aggregates. Under the agreement, Voyager has provided Sangamo with access to a capsid derived from Voyager's proprietary Tracer platform. This capsid has been shown to effectively cross the blood-brain barrier when delivered intravenously in animal models.

08:10 EDT Fiverr launches 'Certified' for freelance certification - Fiverr International announced the launch of Fiverr Certified. Fiverr Certified builds a unique freelance marketplace for each of its tech partners. Freelancers are then certified specifically by those companies, which include Amazon Ads, monday.com, and Stripe, empowering these well-known brands to better support their customers by connecting them with a trusted expert.

08:09 EDT Aqua Metals completes Li AquaRefining recycling pilot - Aqua Metals announced the successful completion of its groundbreaking Li AquaRefining recycling pilot, transition to 24/5 operations and production of high-purity, saleable quantities of sustainably recycled battery materials. The Company completed the pilot facility commissioning with the recovery of both cobalt and manganese dioxide, completing the suite of valuable metals the Company reclaims from spent lithium batteries using its patented AquaRefining technology. The Company has completed the pilot - from finalized design through to operations - in roughly eight months' time, and with a transition to 24-hour operations, is scaling the pilot facility to a capacity of 75 tons per annum of processed black mass input. Based on the success of the pilot, the Company also continues the simultaneous phased development and commissioning of its first commercial-scale facility, which was initiated earlier this year and is well underway. Steve Cotton, President & CEO of Aqua Metals said, "We have secured more than 3,000 tons of black mass to fuel our operations, enough supply to reach commercial scale in 2024. Aqua Metals intends to capitalize on its first-mover advantage, driving US leadership in sustainable battery recycling, and building a robust domestic supply chain for the critical minerals that cleanly power an electrified future."

08:09 EDT Akebia reports Phase 4 results of Auryxia for dialysis patients - Akebia Therapeutics announced topline results from IMPACT, a Phase 4 collaborative study investigating the impact of Auryxia when used as the primary phosphate-lowering therapy, on the utilization of erythropoiesis-stimulating agent - ESA - and intravenous iron as well as on laboratory parameters indicative of phosphate and anemia management vs. the standard of care in adult patients with chronic kidney disease - CKD - on dialysis. Auryxia is approved for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis and for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. Co-primary endpoints were the difference in mean change from baseline to the efficacy evaluation period in monthly ESA and IV iron doses between groups. Treatment with Auryxia resulted in a statistically significant difference in mean monthly ESA use and a non-significant difference in mean monthly IV iron use. Serious adverse events occurred in 39% of patients receiving Auryxia and 59% in those receiving SOC.

08:07 EDT Tevogen, Semper Paratus Acquisition enter merger agreement - Tevogen Bio and Semper Paratus Acquisition announced the execution of a merger agreement. Upon closing of the merger, the combined company will be named Tevogen Bio Holdings. Tevogen Holdings common stock and warrants are expected to be listed on the NYSE under the new ticker symbol "TVGN". Tevogen Bio is currently focused on developing its pipeline using its precision T cell platform, ExacTcell. ExacTcell is a product development toolkit that utilizes CD8+ Cytotoxic T Lymphocytes, also known as Killer T Cells, one of nature's most powerful weapons against cancer and infection. Unlike currently available genetically engineered T cell therapies, the ExacTcell approach is based on careful selection of naturally occurring T cells that recognize targets of interest from the body's native T cell receptor pool and is designed to provide enhanced safety. CD8+ CTLs in ExacTcell-based products also target multiple and distinct antigens to overcome potential mutational challenges. Tevogen Bio's lead product is TVGN 489, an allogeneic, genetically unmodified T cell therapy for the treatment of COVID-19 in highly vulnerable patient populations, such as the immune-compromised, elderly, and infirm, along with potential applications in Long COVID treatment and prevention. Tevogen Bio has completed a proof-of-concept clinical trial for TVGN 489, showing positive results, including no dose-limiting toxicities or significant adverse events related to TVGN 489 observed in any patient at any dose level. TVGN 489 has not been observed to be compromised by any COVID-19 variant to date. Upon completion of the Transaction, Tevogen Bio will be pursuing several late-stage clinical trials, expanding manufacturing capacity, and expediting the development of products targeting life-threatening viral infections, several viral-induced and non-viral-induced common cancers, and multiple sclerosis. Following the closing of the Transaction, Dr. Ryan Saadi, MD, MPH, will serve as the CEO and Chairman of the Board of Directors of Tevogen Holdings. The Board of Directors of Tevogen Holdings is also expected to include Professor Curtis Patton, Susan Podlogar, Victor Sordillo, Lindee Goh, Suren Ajjarapu, and Jeffrey Feike. The Transaction was unanimously approved by the boards of directors of all parties, at an expected combined pro forma enterprise value of approximately $1.2 billion. In connection with the Transaction, Semper Paratus will migrate out of the Cayman Islands, domesticate as a Delaware corporation, and rename itself Tevogen Bio Holdings Inc., and Tevogen Bio will merge with and into a newly formed wholly owned subsidiary of Tevogen Holdings. Additionally, the Transaction includes a contingent earnout in the form of additional equity in Tevogen Holdings payable to the Tevogen Bio stockholders and Semper Paratus' sponsor. The Transaction is expected to be completed in the fourth quarter of 2023, subject to, among other things, receipt of applicable governmental, regulatory, and third-party approvals, satisfaction of minimum closing net tangible asset and cash requirements, and the satisfaction or waiver of other customary closing conditions.

08:06 EDT BioXcel Therapeutics down 67% amid regulatory inquiry into BXCL501 development - In a regulatory 8-K filing, BioXcel Therapeutics states: "In December 2022, the FDA conducted an inspection of one of the clinical trial sites in the Phase 3 TRANQUILITY II clinical trial, where the principal investigator enrolled approximately 40% of the subjects participating in the trial. At the conclusion of this inspection, the FDA issued an FDA Form 483 identifying three inspectional observations. These observations related to the principal investigator's failure to adhere to the informed consent form approved by the Institutional Review Board for a limited number of subjects whose records the FDA reviewed, maintain adequate case histories for certain patients whose records the FDA reviewed, and adhere to the investigational plan in certain instances. For example, the FDA cited the principal investigator's delay in informing the sponsor's medical monitor or pharmacovigilance safety vendor of a serious adverse event for one of the subjects, which report was made to the Company's vendor outside of the 24 hour time period prescribed by the clinical trial protocol. The principal investigator for this clinical site responded to the FDA observations within the time period requested. The FDA inspection remains open, however, as the FDA has not issued an Establishment Inspection Report. In May 2023, it came to the Company's attention that this same principal investigator in the TRANQUILITY II clinical trial may have fabricated email correspondence purporting to demonstrate that the investigator timely submitted to the Company's pharmacovigilance safety vendor a report of an SAE from a different subject than the one cited in the FDA Form 483, and purporting to show that the vendor had confirmed receipt. Upon receipt of this information, the Company promptly initiated an investigation and recently received confirmation that the principal investigator fabricated the email correspondence related to the timing of the reporting of this SAE to the Company's pharmacovigilance vendor to make it appear as though this SAE had been timely reported to the pharmacovigilance vendor as required by the clinical trial protocol. The Company also confirmed that this SAE had been timely entered into the electronic data capture system, even though the SAE had not been separately reported to the Company's pharmacovigilance safety vendor within the 24 hour timeframe required under the protocol. In connection with this ongoing investigation, the Company was made aware that the fabricated email correspondence was provided to the FDA by the principal investigator's employer during the on-site inspection in December 2022. After unblinding of the data, the Company determined that the SAE that was the subject of this fabricated correspondence between the principal investigator and the Company's pharmacovigilance vendor occurred in a subject in the placebo arm. This principal investigator has not participated in any other clinical trial sponsored or conducted by the Company. Moreover, the study was designed such that trained study staff other than principal investigators were to conduct assessments of the primary efficacy measure. The Company is currently in the process of conducting an investigation into protocol adherence and data integrity at the principal investigator's trial site and is in the process of retaining an independent third party to audit the data collected at the site. The Company's ongoing investigation and/or the planned independent audit may uncover new findings regarding the integrity of the trial data from this principal investigator's site, the accuracy of safety or efficacy findings, or the usability of the data in connection with a marketing application. The Company plans to complete its investigation as soon as possible, although the Company can provide no assurance regarding the timing of the completion of its own investigation or the timing of the completion of the planned independent audit of the trial site. Further, the Company has notified the FDA of these findings and the steps it intends to take to validate the integrity of the data generated by this investigator for the TRANQUILITY II trial. The timing of the Company's marketing application and prospects for regulatory approval of BXCL501 for the acute treatment of agitation associated with dementia in patients with probable Alzheimer's disease may be adversely impacted by these developments. For example, even if the Company's investigation and the independent audit conclude that data from the TRANQUILITY II trial have not been affected or compromised by the principal investigator's actions or other deficiencies at the trial site, the FDA may not accept or agree with the Company's conclusions or analyses, or may interpret or weigh their importance differently. Further, if the Company or the FDA determines that there are issues with data integrity and/or compliance with good clinical practice requirements at the trial site, the Company may be unable to use some or all of the subject data generated at this clinical site to support a marketing application. If all or a substantial portion of such data were discarded, the TRANQUILITY II trial may no longer be adequately powered for statistical significance and the Company may need to conduct a new clinical trial. If the Company conducts a new Phase 3 trial, such trial may have different safety or efficacy results from the topline data the Company is announcing today. Topline data from the TRANQUILITY II trial, including results from subjects at this principal investigator's site, may not be predictive of the results in any new trial. Further, any investigation, disqualification or debarment of, or proceeding or action against the principal investigator, or any investigation, proceeding or action against the Company, could further delay development and approval of BXCL501 for this indication, and otherwise have a material adverse effect on the Company, its financial condition, results of operations and prospects." Shares of BioXcel Therapeutics are down 67% in pre-market trading following the disclosure that accompanied topline results for BXCL501 in acute treatment of Alzheimer's Disease-related Agitation.

08:06 EDT Oppenheimer Holdings announces preliminary results from Dutch acution - Oppenheimer Holdings announced preliminary results of its modified "Dutch auction" tender offer which expired at 11:59 p.m., New York City time, on Wednesday, June 28, 2023. Based on the preliminary count by Computershare Trust Company, N.A., the depositary for the tender offer, a total of 437,183 shares of the company's Class A non-voting common stock, par value $0.001 per share, were properly tendered and not properly withdrawn at or below a purchase price of $40.00 per Share, including 8,143 Shares that were tendered by notice of guaranteed delivery. In accordance with the terms and conditions of the tender offer and based on the preliminary count by the Depositary, the company expects to purchase 437,183 Shares through the tender offer at a price of $40.00 per Share, for an aggregate cost of approximately $17.49M, excluding fees and expenses relating to the tender offer. As the company expects to accept for purchase all of the Shares which were properly tendered and not properly withdrawn at a price at or below $40.00 there is no proration factor. The total of 437,183 Shares that the company expects to purchase represents approximately 4.0% of the company's currently outstanding Shares as of June 28, 2023.

08:05 EDT Xortx Therapeutics announces results of annual, special meeting - XORTX Therapeutics announced the results of its annual and special meeting of shareholders held Wednesday, June 28, 2023. A total of 7,482,990 common shares of the Company were represented at the Meeting, representing approximately 41.6% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including election of all six management nominees to the board of directors of the Company, the appointment of Smythe LLP as auditors of the Company for the ensuing year and authorization of the directors to fix their remuneration, and re-approval of the stock option plan.

08:03 EDT Eiger BioPharmaceuticals to focus on avexitide, names David Apelian as CEO - Eiger BioPharmaceuticals announced that following an extensive portfolio prioritization review, the company will focus its development efforts on advancing avexitide in hyperinsulinemic hypoglycemia indications. The company will continue to commercialize Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies. In addition, Eiger is evaluating strategic partnering options for its virology assets, lonafarnib and peginterferon lambda. A 25% reduction in workforce, a reduction in out-of-pocket spending related to its hepatitis delta development program and its existing term loan are expected to extend the company's cash runway into the fourth quarter of 2024. The company also announced that it has appointed David Apelian, MD, PhD, MBA, who has served as interim CEO since December 2022, as the company's next CEO.

08:03 EDT Navidea rejects ProPhase Labs offer to acquire certain Navidea assets - ProPhase Labs (PRPH) announced that it recently made an unsolicited offer to acquire certain assets from NYSE American listed Navidea Biopharmaceuticals (NAVB) and that the offer was rejected by Navidea. On June 8, 2023, ProPhase submitted to Navidea a written, non-binding offer to purchase a portion of the assets of Navidea. Prophase offered a purchase price of either: $7 million, if paid in cash, or alternatively, $9.1 million, if paid in shares of common stock, par value $0.0005 per share, of ProPhase. ProPhase advised Navidea that it would be amenable to a purchase price paid in a combination of cash and ProPhase Stock. The cash offer was equivalent to over two times the then-current market cap of Navidea or almost three times the current market capitalization of Navidea in ProPhase Stock. Furthermore, the offer would have left Navidea with other assets of Navidea such as the current and future milestone payments, the majority of the therapeutic assets, the cardiovascular products, and any territories Lymphoseek assets are already committed to. On June 16, 2023, Navidea informed ProPhase that the board of directors of Navidea flatly rejected the offer. Navidea did not make a counteroffer and did not seek to engage in any further discussions with Prophase. ProPhase made this offer because ProPhase believes that it has the infrastructure, platform, distribution and capital needed to successfully develop the targeted Navidea assets. ProPhase included the opportunity for Navidea to take some or all of the transaction value in ProPhase Stock, so that Navidea could share in the upside from the development of the Navidea assets by ProPhase, as well as participate in the upside from ProPhase's already-successful lines of business.

08:00 EDT Semper Paratus Acquisition Corp trading halted, news pending

07:37 EDT Nextech3D.ai announces new 3D modeling deals - Nextech3D.AI announced that it has surpassed over 37,700 3D models delivered to its customers in various e-commerce industries and sees significant growth potential ahead as hundreds of millions of products go 3D as merchants are pivoting from 2D flat photos to 3D experiences in the e-commerce marketplace.

07:35 EDT Sonder Holdingsto launch four new properties across Florida - Sonder Holdings is launching four new properties across Florida. This will bring the company's footprint in the state to 930 live units across hotel, resort and multi-unit serviced apartment properties, hosting a diverse group of travelers including leisure, business, and conference guests..."We're seeking further expansion opportunities in Florida, including in Tampa, St. Pete, Sarasota, Clearwater Beach, Naples, Jacksonville, the Florida Keys, and the Palm Beaches. We're particularly interested in existing hotel takeovers and large multifamily developments with construction already underway. We offer a variety of deal structures to meet the needs of both owners and lenders in the current economic climate," said Peter Debs, Senior Director of Real Estate at Sonder.

07:33 EDT Mattr invests in Connection Technologies segment producion capabilities - Shawcor Ltd., dba Mattr Infratech, will expand and enhance its Connection Technologies segment production capabilities in the US and Canada, with commitments for two new operating facilities which, in combination, will replace its existing Greater Toronto Area manufacturing site that was sold and leased-back in June of 2022. Capital expenditures for these operating facilities are expected to represent, in the aggregate, approximately $35 million across 2023 and 2024. The 2023 portion of these organic growth investments form a part of the Company's previously communicated capital expenditure guidance of $160-$180 million for the current year. These facilities will expand the Company's capability to deliver high-quality heat and cold shrink tubing and highly specified custom wire and cable products to the North American market, more specifically: Its Shawflex business will be relocating to a larger, more efficient facility in Vaughan, Ontario. This new site will also house Kanata Electronic Services Ltd,, which was recently acquired and is being integrated into the Shawflex business. The Shawflex business manufactures highly specified custom wire and cable products and assemblies for complex applications and extreme environments, and; Its DSG-Canusa business will be relocating its North American manufacturing footprint from the GTA to a larger, more efficient facility in Fairfield, Ohio, moving closer to its primary vendors and the majority of its customers. This new site will also house the business's North American distribution hub, which will relocate from Loveland, Ohio. The DSG-Canusa business manufactures high-quality heat & cold shrink tubing products and accessories for automotive, communications, electrical utility, electronic and energy markets. Equipment will be relocated from the Company's current GTA site to the new facilities in a phased manner, and both facilities are expected to be operational in 2025. They are expected to approach normalized initial levels of production during 2026. The Company believes that, in combination, these facilities with initial equipment installations, have the potential to enable over $50 million of incremental annual revenue generating capacity as they approach efficient utilization levels.

07:20 EDT Flyht Aerospace receives $1.4M purchase order from OEM partner - FLYHT Aerospace Solutions received a purchase order valued at $1.4M for Iridium modems and license fees from a long-time OEM partner. This order builds upon the relationship previously discussed in press releases dated July 15, 2014, August 1, 2019, February 18, 2020, July 6, 2021, October 6, 2021 and May 4, 2022. Under the terms of the existing agreement, the OEM customer will be licensing FLYHT's technology and delivering the AFIRS 228S system to their European airframer customer for three certified aircraft platform types. The products are scheduled for delivery throughout the remainder of 2023.

07:17 EDT Peraso, Tachyon announce production of PtP, PtMP solutions - Peraso and Tachyon Networks together have announced production readiness of the TNA-30X product family from Tachyon, new Point-to-Point and Point-to-Multipoint solutions utilizing Peraso's mmWave technology for 60GHz unlicensed Fixed Wireless Access networks. Peraso's 60GHz solutions focus on accelerating time to market and reducing the cost of designing a module that must be manufactured in high volume, while providing unmatched quality and reliability. The Company's antenna modules offer low latency, high reliability, multi-gigabit throughput and can be configured to support Peraso's unique capabilities that enable PtP and PtMP FWA applications.

07:16 EDT NeoGenomics appoints Elizabeth Floegel, Neil Gunn, Tony Zook to board - NeoGenomics announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors. The Board has elected three new independent board members to join the board effective June 29, 2023. Elizabeth Floegel, Chief Information & Digital Officer of Numotion, a complex rehabilitation technology provider, will be a member of the Audit & Finance and Compliance Committees. Neil Gunn, former CEO of IDbyDNA, a developer of metagenomic technology for infectious disease testing and pathogen surveillance which was acquired by Illumina in 2022, will be a member of the Culture & Compensation and Nominating and Corporate Governance Committees. Tony Zook, former CEO of Innocoll Pharmaceuticals, a pharmaceutical manufacturing company focused on postsurgical pain management, will be a member of the Audit & Finance and Culture & Compensation Committees.

07:13 EDT Rallybio co-founder Stephen Uden appointed CEO, effective August 1 - Rallybio announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1. Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. The Company does not expect to hire a replacement for Dr. Uden's current role. He will succeed Martin Mackay, Ph.D., Chief Executive Officer, Chairman of the Board, and Co-Founder, who will assume the role of Executive Chairman. As Executive Chairman, Dr. Mackay will remain a full-time employee and continue to be actively involved with the Company, with a particular focus on company strategy, investor relations and related activities.

07:12 EDT Mobilicom launches MCU-70 SDR product - Mobilicom announced the launch of its latest product, the MCU-70, the latest in its MESH Networking Cybersecure Software Defined Radio Series delivering high-performance wireless communications. With its relatively small size and lightweight design, MCU-70 delivers superior performance for mid-sized and long-range unmanned aerial vehicles where form-factor-to-capability performance is critical. Designed for durability in rugged outdoor environments, MCU-70's communications range of up to 100 miles/150km equips drones with the communications needed for new missions and applications, expanding Mobilicom's addressable markets for both commercial and military applications.

07:11 EDT Plus Therapeutics reports interim updates from two ReSPECT trials - Plus Therapeutics reported positive interim updates from the ReSPECT-GBM and ReSPECT-LM clinical studies evaluating the Company's lead radiotherapeutic, rhenium obisbemeda, for the treatment of recurrent glioblastoma and leptomeningeal metastases at the Society of Nuclear Medicine & Molecular Imaging, SNMMI, Annual Meeting, which took place June 24-27, 2023 in Chicago, Illinois. An oral presentation titled, Safety and Feasibility Results from a Phase 1/2 Clinical Trial of 186RNL Obisbemeda in Recurrent Glioma: The ReSPECT-GBM Trial [P988], brief highlights include: Data from 21 patients in the Phase 1 trial used to support the recommended Phase 2 trial dose for patients with tumor volumes less than or equal to20 mL was presented. A single dose of rhenium obisbemeda was generally safe and well-tolerated, with no dose-limiting toxicities and minimal systemic radiation exposure. The data demonstrates efficacy signals in a prognostically unfavorable patient population. The median overall survival in all 21 patients was 11 months or a 38% increase in OS versus a median OS of approximately 8 months for standard of care in rGBM. Median OS in patients receiving greater than100 Gy of absorbed radiation dose was 76 weeks versus 22 weeks for those receiving less than100 Gy. Increased absorbed radiation dose and percent tumor volume treated correlates with improvement in overall survival, specifically: For each 100 Gy increase of Total Dose in Distribution Volume, the risk of death decreases by 45.6%. For each 10% increase in the Ratio of Treated to Total Tumor Volume, the risk of death decreases by 66.9%. A poster presentation titled, Preliminary Clinical Data in The Phase 1/2a Dose Escalation Trial of 186RNL Obisbemeda in Leptomeningeal Metastases: The ReSPECT-LM Trial, includes data that showed: Interim results from 10 patients in the Phase 1 trial show a single treatment with rhenium obisbemeda decreased cerebrospinal fluid tumor cell count and was well-tolerated in patients with LM. Rhenium obisbemeda doses administered through an intraventricular catheter showed prompt, complete and durable distribution throughout the CSF through Day 7. A single rhenium obisbemeda administered dose between 6.6 mCi and 26.4 mCi achieved absorbed doses of up to 88.98 Gy to the ventricles and cranial subarachnoid space. No dose limiting toxicities were observed and safety observations were generally minor and resolved. Phase 1/Part B, for continued dose escalation, will open following review by the U.S. Food and Drug Administration, and repeated dosing will be explored. An expansion in Cohort 3 is currently enrolling eligible patients.

07:08 EDT Climb Channel Solutions partners with AppOmni - Climb Channel Solutions, a wholly owned subsidiary of Climb Global Solutions, has announced a new partnership with SaaS security provider, AppOmni. With AppOmni, Climb now offers universal security across all SaaS applications with centralized visibility and data access management. "Climb is always on the lookout for top notch security solutions for our resellers," says Dale Foster, CEO at Climb Channel Solutions. "Adding AppOmni to our transacting vendors list not only provides cutting-edge security solutions for our valued resellers, but this collaboration opens doors for our resellers to tap into the growing demand for compliance, robust security, and visibility sought by IT and security teams."

07:08 EDT Wallbox says Pulsar Plus EV charger to be available at Costco - Wallbox (WBX) announced that Pulsar Plus EV charger, will be available at Costco (COST) stores across the U.S. and through Costco.com starting in July, marking Costco's most extensive EV charging deployment to date. "We continue to see exceptional demand for Pulsar Plus across the U.S. because of its compact form factor, energy management features, and easy installation," said Brett Graessle, VP of Partnerships and Business Development for Wallbox. "Partnering with one of the most popular membership warehouse clubs, like Costco, enables us to expand our distribution footprint and connect with a broader consumer audience. We're excited to bring Pulsar Plus to millions of Costco members across the entire U.S. "

07:06 EDT Ginkgo Bioworks' Enzyme Services selected by Israel's Ambrosia Bio - Ginkgo Bioworks and Ambrosia Bio, an Israeli foodtech company developing novel bioprocesses for the global sugar replacement industry, announced that Ambrosia Bio will leverage Ginkgo Enzyme Services, including its proprietary chassis organisms, to develop an expression strain for the scalable production of the Ambrosia Bio proprietary enzymes used for the conversion of feedstock into allulose. Allulose is an FDA-approved rare sugar that is found in figs, raisins, wheat, maple syrup, and molasses but occurs naturally only in small amounts. Unlike other currently available sweeteners, allulose has a low caloric value - typically under 10% compared to equivalent amounts of sucrose. Over the past three years of stealth mode development, Ambrosia Bio has developed a bioprocess to convert lower-margin feedstocks into rare sugars and specialized ingredients such as allulose. To further optimize its process, Ambrosia Bio will leverage Ginkgo Enzyme Services, an end-to-end service powered by throughput screening and machine learning-guided protein design, to aid its goal of producing an optimized version of its proprietary enzyme in a productive expression strain.

07:05 EDT Genenta Science receives Orphan Drug Designation from EC for Temferon - Genenta Science announced that the European Commission has granted Orphan Drug Designation to Temferon for the treatment of glioma. Glioblastoma Multiforme is the first clinical indication of Temferon. GBM is the most common malignant primary brain tumor and the most aggressive diffuse glioma, with unmethylated MGMT promoter status identified in approximately 60% of the GBM population. Temferon is Genenta's product at the most advanced stage of development and consists of the patient's own stem progenitor cells modified with Genenta's platform to express interferon alpha within solid tumors. IFNa is a well-known immunomodulatory protein that has been used in the clinic for decades for the treatment of a variety of cancers, but with limited current use because of the systemic toxicity. Genenta's platform is designed to avoid systemic toxicity and selectively deliver therapeutic activity within the solid tumor. From pre-clinical experiments, it has been observed that Temferon breaks tumor-induced tolerance, thus allowing the immune system to recognize the tumor and mount a durable immune response.

07:05 EDT Marqeta appoints Karna Crawford as Chief Marketing Officer - Marqeta announced that it had appointed Karna Crawford, a marketing executive who has held leadership roles at J.P. Morgan Chase, Verizon and Ford, as it's Chief Marketing Officer. Crawford will be a crucial member of Marqeta's senior leadership team driving the company's global marketing efforts, including marketing and brand strategy, demand generation, product marketing, and communications.

07:03 EDT TScan Therapeutics CFO Brian Silver to depart - TScan Therapeutics announced that its CFO Brian Silver, will be leaving the Company, effective July 21, 2023, to pursue a new opportunity at an advisory firm based in New York, where he lives with his family. Brian will continue to be available to provide strategic advice for the Company. The Company has initiated a search for a successor CFO.

07:01 EDT Canopy Growth appoints PKF O'Connor Davies as auditor - Canopy Growth announced the appointment of PKF O'Connor Davies as its independent registered public accounting firm for the 2024 fiscal year and accepted the resignation of KPMG. "This change has been underway for some time and reflects a joint decision between Canopy Growth and KPMG. We are pleased to welcome PKFOD, which has specific experience in supporting clients in the cannabis industry as our accounting firm for fiscal 2024. Going forward, we remain focused on our ongoing actions to strengthen Canopy Growth's balance sheet and advance towards profitability" said Judy Hong, CFO, Canopy Growth.

06:53 EDT Eli Lilly to acquire Sigilon Therapeutics for $14.92 per share in cash - Eli Lilly (LLY) and Sigilon Therapeutics (SGTX) announced a definitive agreement for Lilly to acquire Sigilon. Since 2018, Lilly and Sigilon have worked together to develop encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. Under the terms of the definitive agreement, Lilly will commence a tender offer to acquire all outstanding shares of Sigilon for a purchase price of $14.92 per share in cash payable at closing, plus one non-tradeable contingent value right, or CVR, per share that entitles the holder to receive up to an additional $111.64 per share in cash, for a total potential consideration of up to $126.56 per share in cash without interest. CVR holders would become entitled to receive the following contingent payments: $4.06 per share in cash, upon first dosing of a specified product in the first human clinical trial; $26.39 per share in cash, upon first dosing of a specified product in the first human clinical trial for registration purposes; and $81.19 per share in cash, upon receipt of the first regulatory approval of a specified product. There can be no assurance that any payments will be made with respect to the CVRs. The transaction is not subject to any financing condition and is expected to close in the third quarter, subject to customary closing conditions, including that Lilly owns a majority of the outstanding shares of Sigilon's common stock following the tender offer. Following the successful closing of the tender offer, Lilly will acquire any shares of Sigilon it does not already own through a second-step merger at the same consideration as paid in the tender offer. Sigilon's board of directors unanimously recommends that Sigilon's stockholders tender their shares in the tender offer. Lilly will determine the accounting treatment of this transaction as a business combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally Accepted Accounting Principles upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance.

06:48 EDT Lindsay sees sales volume in Brazil to increase in Q4 - CEO Wood concluded, "As we are now in the growing season in North America, demand in our fourth quarter is expected to be driven primarily by summer crop harvest and storm damage replacement, which we are expecting to be lower than the exceptional demand we experienced in last year's strong fourth quarter. The potential impact from continuing drought conditions could provide additional demand support. We expect sales volume in Brazil to increase in the fourth quarter, supported by the new government financing program that was recently announced. Demand across other international markets continues to be supported by positive agricultural market fundamentals and continuing global concerns over food security and global grain supplies. The impact of increased U.S. infrastructure spending and the strength of our project sales funnel support the long-term growth outlook for our infrastructure business. The timing of project execution at the state level can be difficult to predict and, because of delayed startups we have experienced to date, we expect a limited positive impact on our fiscal 2023 results and a more meaningful positive impact in fiscal 2024 and beyond."

06:32 EDT Kineta to Receive $5M milestone payment from Merck - Kineta (KA) achieved a development milestone which triggers a $5M payment from its research and development collaboration with Merck (MRK). This collaboration, focused on the discovery and development of novel candidates for the treatment of amyotrophic lateral sclerosis - ALS -, originated from an agreement between Yumanity Therapeutics and Merck. Following this milestone, Merck will assume sole responsibility for all future development and commercialization of the ALS program. Under the collaboration and license agreement, Kineta is eligible to receive additional milestone payments totaling up to $255M associated with the successful development of marketed products for pipeline programs, as well as royalties on worldwide net sales.

06:13 EDT Greenbrier increases quarterly dividend 11% to 30c per share - Board increases quarterly dividend by 11% to 30c per share, payable on August 8 to shareholders of record as of July 18. Represents Greenbrier's 37th consecutive quarterly dividend.

06:08 EDT MediciNova's MN-166 does not show efficacy in alcoholism trial - MediciNova presented the results of the Phase 2b trial of MN-166 - ibudilast - in alcohol use disorder at the 46th Annual Research Society on Alcoholism Scientific Meeting held June 24 - 28 in Bellevue. The clinical trial was funded by the National Institute on Alcohol Abuse and Alcoholism, a component of the National Institutes of Health. The primary objective of the trial was to evaluate the effects of MN-166 vs. placebo on percent heavy drinking days over the course of a 12-week treatment period. MN-166 treatment was not superior to placebo for reducing percent heavy drinking days. Also, MN-166 treatment was not superior to placebo for the secondary endpoints.

06:04 EDT Arcline stands behind proposal to acquire Circor for $57.00 per share - Arcline announced a binding proposal to acquire 100% of the shares of Circor for $57.00 per share. Arcline fully expects to receive the regulatory approvals needed to close its potential acquisition of Circor. Any potential overlap with portfolio companies of Arcline represents a negligible portion of Circor's business, which operates in a highly competitive and fragmented sector. In addition, Arcline's proposal is not contingent on obtaining financing. Consequently, Arcline's offer presents no meaningful execution risk to Circor's shareholders.

06:04 EDT Rockwell Medical announces 3-year co-promotional pact with B. Braun Medical - Rockwell Medical announced that the company entered into a three-year co-promotion services agreement with B. Braun Medical, a company involved in renal therapies including innovative, high-quality products for hemodialysis. As part of the agreement, Rockwell Medical designates B. Braun as an independent, non-exclusive representative to promote the Company's hemodialysis concentrates products to dialysis providers in the United States, concertedly on the west coast. All terms of the sale of any Rockwell Medical product, including price, delivery schedule, and terms and conditions, are set by Rockwell Medical, at the Company's sole discretion. All orders will be directed to, and processed by, Rockwell Medical. B. Braun will receive a fee for any sales generated by its promotional efforts.

05:12 EDT Lordstown Motors receives approval of first day motions - Lordstown Motors (RIDE) announced that the United States Bankruptcy Court for the District of Delaware entered orders granting approval, on an interim or final basis, of all of the company's "first day" motions filed in its chapter 11 cases on June 27. Lordstown continues to operate with significant unencumbered cash-on-hand. Additionally, the court granted interim approval of the company's first day employee wages and benefits motion, which enables the company to continue paying all employee wages, salaries, and providing benefits - without interruption. The hearing for final approval of that motion is scheduled for July 27. Bankruptcy courts routinely grant final approval of the relief requested. The company can also continue paying suppliers/vendors for all authorized goods delivered and services rendered after the filing date of June 27. Following the hearing, the company is prepared to turn its attention to the expedited marketing and sale process for its assets, including the Endurance assets, as proposed in the company's motion for approval of that process filed on the petition date. The company is also poised to continue vigorously pursuing its pending litigation against global technology company Hon Hai Technology Group (HNHPF) and certain of its affiliates.

05:03 EDT Yalla showcases 'Merge Kingdoms' at DEF - Yalla announced it showcased its new hard-core game, "Merge Kingdoms", at the Dubai Esports and Games Festival, or DEF, 2023, MENA's premier esports and gaming event.